[Hypercalcemia after hyperkalemia].
| Autor: | de Groot DM; Amphia, afd. Interne Geneeskunde, Breda., Beugelink L; Amphia, afd. Interne Geneeskunde, Breda., van Etten RW; Amphia, afd. Interne Geneeskunde, Breda.; Contact: Ronald W. van Etten (rvanetten@amphia.nl). |
|---|---|
| Jazyk: | Dutch; Flemish |
| Zdroj: | Nederlands tijdschrift voor geneeskunde [Ned Tijdschr Geneeskd] 2022 Jun 21; Vol. 166. Date of Electronic Publication: 2022 Jun 21. |
| Abstrakt: | Background: Hyperkalemia is a common yet dangerous phenomenon in patients with chronic kidney disease (CKD). Patients suffering from CKD are therefore often treated with potassium-binding supplements such as calcium polystyrene sulfonate (CPS). Hypercalcemia is a known side effect of CPS. However, the increase in serum calcium is usually small. Case Description: A 68 year old male patient suffering from CKD was treated with a daily administration of 80mg CPS. He presented with complaints of a dry mouth, thirst and malaise. Blood tests showed an elevated serum calcium of 3,25 mmol/L (2,15- 2,55 mmol/L). Additional diagnostics revealed no abnormalities. The hypercalcemia was attributed to the use of CPS only after the exclusion of a wide differential diagnosis. Conclusion: Although CPS induced hypercalcemia is usually mild, a more severe course is possible. Knowledge about the composition of medication is paramount to prevent such side effects. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|